New PET tracers for neuroimaging of FAAH in endocannabinoid signaling
New PET tracers for neuroimaging of FAAH in endocannabinoid signaling
批准号:
8852588
负责人:
Steven H Liang
金额:
$18.54万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-07-01 至 2019-06-30
关键词:
AcuteAnimalsAreaBindingBiochemical ProcessBiodistributionBiologicalBiological AssayBrainCannabinoidsCarbamatesCarbonCarbon DioxideClinicalClinical ResearchConsciousCyclotronsDataDevelopmentDiseaseDoseDrug AddictionDrug KineticsDrug abuseDrug userEndocannabinoidsEnzyme InhibitionEnzymesEvaluationFacultyFluorineGenetic studyGoalsHalf-LifeHealthHumanHuman ResourcesHydrolase GeneImageImaging TechniquesIn VitroK-Series Research Career ProgramsKineticsLabelLaboratoriesLeadLibrariesLifeLinkMeasuresMediatingMedicalMedical ImagingMental disordersMentorsMetabolicModelingMulticenter TrialsMutationNational Institute of Mental HealthNeurologicNeurotransmittersNew AgentsPathway interactionsPatient CarePatientsPharmaceutical PreparationsPharmacologic SubstancePlasmaPlayPopulationPositioning AttributePositronPositron-Emission TomographyPreclinical Drug EvaluationProcessPropertyProteinsPsychotropic DrugsPublic HealthQualifyingRadioactiveRadiolabeledRadiopharmaceuticalsRattusReactionRecordsRegulationRelative (related person)ResearchResearch SubjectsResourcesRiskRodentRoleScienceScientific Advances and AccomplishmentsSignal PathwaySignal TransductionSiteSystemTechniquesTestingTherapeuticTimeTracerTrainingUnited StatesUreaWorkaddictionanandamidebasebench to bedsidedensitydesignfatty acid amide hydrolaseimprovedin vivoin vivo imaginginhibitor/antagonistinsightmemberneuroimagingnonhuman primatenovelnucleophilic substitutionpreclinical studyprogramsradiotracerresearch facilitysample fixationstatisticstargeted imagingtooluptake
中文摘要
描述(由申请人提供):K01研究的目标是帮助申请人在神经和精神疾病的PET示踪剂开发和神经成像方面建立一个独立的和高度竞争的研究项目,主要重点是开发一种最佳的放射性药物,用于研究内源性大麻素(eCB)信号中脂肪酸酰胺水解酶(FAAH)的PET成像研究。FAAH是一种酶,负责水解内源性大麻素,如anandamide。因此,它在确定人类大脑中大麻素系统的基调方面起着重要作用。抑制FAAH被认为是一个有吸引力的药物和成像目标。此外,有大量证据表明FAAH在成瘾以及其他精神和神经疾病中起着重要作用。测量活人大脑中FAAH水平的能力将是非常有用的。不仅可以直接测量潜在的FAAH抑制剂药物的疗效,而且可以将FAAH在某些人群中的作用与正常人群进行比较(例如,吸毒者与非吸毒者),从而深入了解这种重要酶在正常和患病受试者中的作用。FAAH可以通过医学成像技术——正电子发射断层扫描(PET)来测量人脑中的FAAH,这种技术可以产生体内发生的生化过程的图像。已经开发了几种放射性示踪剂用于FAAH的PET成像。迄今为止,只有Neil Vasdev博士开发的碳11 (11C;半衰期= 20.4分钟)标记的放射性示踪剂([11C]CURB)已经在人体试验中进行了测试和验证。[11C]CURB的试点数据证明了FAAH成像的可行性和临床潜力。为了克服[11C]CURB基于磷的局限性,开发了第一个氟-18 (18F;半衰期= 109.7 min)放射性标记的FAAH抑制剂[18F]DOPP。对[18F]DOPP在非人灵长类动物中的初步评价表明,该放射性示踪剂是一种有前景的铅示踪剂,值得进一步优化和评估,用于疾病表现时eCB信号通路急性变化的特异性成像。该建议包括培训一名初级教员,从实验室到床边进行PET神经成像研究,并为放射性药物科学领域做出贡献;严重缺乏高素质人才的领域。申请人亦可利用香港国际一流的教育资源、在科研及辅导方面有成功经验的教师,以及一流的研究设施,进行拟进行的研究。本K01方案的具体目标是设计、合成和开发具有优化动力学的氟化FAAH抑制剂,用18F对最有希望的先导化合物进行放射性标记,并在非人灵长类动物中对这些化合物进行评价。我们将确定18f标记的FAAH抑制剂的分布、特异性结合和动力学模型,这将使我们能够研究FAAH相关的内源性大麻素调节成瘾的机制。相关性:该提案有可能通过使用18f标记的FAAH示踪剂推进PET神经成像来改善公众健康并帮助患有成瘾的患者。
英文摘要
DESCRIPTION (provided by applicant): The goal of the K01 research is to help the applicant to establish an independent and highly- competitive research program in the PET tracer development and neuroimaging for neurologic and psychiatric illnesses, with a major focus of developing an optimal radiopharmaceutical for PET imaging study of fatty acid amide hydrolase (FAAH) in the endocannabinoid (eCB) signaling of drug addiction. FAAH is the enzyme responsible for hydrolysing endocannabinoids such as anandamide. As such it plays a major role in setting the tone of the cannabinoid system in the human brain. Inhibition of FAAH is seen as an attractive pharmaceutical and imaging target. In addition there is substantial evidence that FAAH plays a major role in addiction, and in other psychiatric and neurological illnesses. The ability to measure the levels of FAAH in the living human brain would be extremely useful. Not only could the efficacy of potential FAAH inhibitor drugs be measured directly, but the role of FAAH in certain populations could be compared to normal populations (e.g. drug users compared to non-users), affording insights into the role of this important enzyme in normal and diseased subjects. FAAH could be measured in the human brain by the medical imaging technique, positron emission tomography (PET), which creates images of biochemical processes occurring in vivo. Several radiotracers have been developed for PET imaging of FAAH. To date, only carbon-11 (11C; half-life = 20.4 min) labeled radiotracer, [11C]CURB developed by Dr. Neil Vasdev, has been tested and validated in human trials. Pilot data with [11C]CURB demonstrated both the feasibility, and clinical potential, of imaging FAAH. To overcome the PK-based limitations of [11C]CURB, the first fluorine-18 (18F; half-life = 109.7 min) radiolabeled FAAH inhibitor [18F]DOPP was developed. Preliminary evaluation of [18F]DOPP in nonhuman primates showed that this radiotracer is a promising lead radiotracer worthy of further optimization and evaluation for specific imaging of acute changes in eCB signaling pathways on disease presentation. This proposal involves training a junior faculty member in PET neuroimaging studies from bench to bedside and contributing to the field of radiopharmaceutical sciences; a field suffering from a critical shortage of highly qualified personnel. The applicant will also take advantage of the world-class educational resources, faculty members with successful track-records in scientific research and mentoring, and top-tier research facilities to conduct the proposed research. It is the specific aim of this K01 proposal t design, synthesize, and develop fluorinated FAAH inhibitors with optimized kinetics, radiolabel the most promising lead compounds with 18F and evaluate these compounds in nonhuman primates. We will determine the distribution, specific binding and kinetic model of 18F-labeled FAAH inhibitor that will enable us to study mechanisms for FAAH-linked endocannabinoid regulation of addiction. Relevance: This proposal has the potential to improve public health and help patients suffering from addiction through advancement of PET neuroimaging using 18F-labeled FAAH tracer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Subtype-Selective Metabotropic Glutamate Receptor PET Ligands
-
批准号:10576674
-
项目类别:
-
资助金额:$81.64万
-
财政年份:2023
-
负责人:Steven H Liang
-
依托单位:
Glycogen synthase kinase 3 ligand discovery for Alzheimer’s disease
-
批准号:10637434
-
项目类别:
-
资助金额:$232.34万
-
财政年份:2023
-
负责人:Steven H Liang
-
依托单位:
Subtype-selective phosphodiesterase PET ligands
-
批准号:10568308
-
项目类别:
-
资助金额:$78.25万
-
财政年份:2023
-
负责人:Steven H Liang
-
依托单位:
Subtype-selective NMDA ligands for Alzheimer's Disease
-
批准号:10593906
-
项目类别:
-
资助金额:$78.1万
-
财政年份:2022
-
负责人:Steven H Liang
-
依托单位:
In vivo Probe for ionotropic glutamate signaling system: AMPA receptors
-
批准号:10584340
-
项目类别:
-
资助金额:$78.86万
-
财政年份:2022
-
负责人:Steven H Liang
-
依托单位:
Subtype-selective NMDA ligands for Alzheimer's Disease
-
批准号:10355691
-
项目类别:
-
资助金额:$78.22万
-
财政年份:2022
-
负责人:Steven H Liang
-
依托单位:
PET ligand discovery for arginine vasopressin
-
批准号:10641669
-
项目类别:
-
资助金额:$121.41万
-
财政年份:2022
-
负责人:Steven H Liang
-
依托单位:
PET imaging of ionotropic glutamate receptor signaling in Alzheimer's disease
-
批准号:10574694
-
项目类别:
-
资助金额:$23.48万
-
财政年份:2022
-
负责人:Steven H Liang
-
依托单位:
PET ligand discovery for arginine vasopressin
-
批准号:10356395
-
项目类别:
-
资助金额:$104.31万
-
财政年份:2022
-
负责人:Steven H Liang
-
依托单位:
PET Imaging for neuroinflammation in Alzheimer's disease
-
批准号:10653556
-
项目类别:
-
资助金额:$19.56万
-
财政年份:2022
-
负责人:Steven H Liang
-
依托单位:
PET imaging for neuroimmune function in Alzheimer's disease
-
批准号:10474697
-
项目类别:
-
资助金额:$43.04万
-
财政年份:2022
-
负责人:Steven H Liang
-
依托单位:
PET Imaging for neuroinflammation in Alzheimer's disease
-
批准号:10301580
-
项目类别:
-
资助金额:$24.66万
-
财政年份:2021
-
负责人:Steven H Liang
-
依托单位:
Supplement for Ligand discovery for delineating cholesterol homeostasis in the brain
-
批准号:10613677
-
项目类别:
-
资助金额:$34.93万
-
财政年份:2021
-
负责人:Steven H Liang
-
依托单位:
Ligand discovery for delineating cholesterol homeostasis in the brain
-
批准号:10658329
-
项目类别:
-
资助金额:$3.91万
-
财政年份:2021
-
负责人:Steven H Liang
-
依托单位:
AMPAR ligand discovery for Alzheimer's disease
-
批准号:10280112
-
项目类别:
-
资助金额:$38.42万
-
财政年份:2021
-
负责人:Steven H Liang
-
依托单位:
Ligand discovery for delineating cholesterol homeostasis in the brain
-
批准号:10605057
-
项目类别:
-
资助金额:$77.48万
-
财政年份:2021
-
负责人:Steven H Liang
-
依托单位:
AMPAR ligand discovery for Alzheimer's disease
-
批准号:10666328
-
项目类别:
-
资助金额:$194.94万
-
财政年份:2021
-
负责人:Steven H Liang
-
依托单位:
Ligand discovery for delineating cholesterol homeostasis in the brain
-
批准号:10604811
-
项目类别:
-
资助金额:$76.01万
-
财政年份:2021
-
负责人:Steven H Liang
-
依托单位:
MAGL PET tracer-guided prognosis and neuroprotective therapy for Alzheimer's disease
-
批准号:10169589
-
项目类别:
-
资助金额:$16.37万
-
财政年份:2019
-
负责人:Steven H Liang
-
依托单位:
MAGL PET tracer-guided prognosis and neuroprotective therapy for Alzheimer's disease
-
批准号:10001417
-
项目类别:
-
资助金额:$16.56万
-
财政年份:2019
-
负责人:Steven H Liang
-
依托单位:
海外基金